Monday, 13 July 2026
  
Login

Australia's most trusted
source of pharma news

Monday, 13 July 2026
News

Four drugs hit with first copycats

Posted 13 July 2026 AM

The TGA has approved the first generic versions of four drugs – one of which is no longer available in Australia and another targeting Pfizer's $233 million franchise.

Cipla has registered the first generic of Pfizer’s Vyndamax used for the treatment of adult patients with wild-type or hereditary transthyretin amyloid cardiomyopathy under two brand names - Cipla Tafamidis and Tafamicip.

To see the whole article, please login

Popular

Butler fires a delisting warning shot
GM tells why it was time to resign
Another GM gone, successor named
20yr road to approval finally ends
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (22)

Access & Reimbursement (1)

Clinical & Medical, R&D (7)

Regulatory, Pharmacovigilance & QA (3)

Other (10)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home